TINAVI has been focusing on the field of orthopedics for 15 years, and has always been committed to providing more possibilities for the development of precision and intelligent orthopedics medicine by integrating innovation into every link from design, research and manufacture with the spirit of persevering original research.
As the pioneer of medical robots in China, TINAVI has obtained more than 100 patents, more than 20 national and provincial key scientific research projects, and is the supporting organization of National & Local Joint Engineering Research Center for Medical Robots. TINAVI has its own postdoctoral scientific research workstation, and is a member of National Robotics Standardization General Working Group of China, a deputy-director level member company of the Medical Robot Branch of the Chinese Society of Biomedical Engineering, deputy-director level member company of the Beijing Intelligent Robot Industry Alliance, and director level member company of the Zhongguancun Medical Device Industry Alliance.
TiRobot Orthopaedic Robotic System can help surgeons precisely position surgical instruments or implants during orthopedic surgeries for spine and trauma with its robotic arm.
The system is compatible to 2D and 3D modes. With the aid of an orthopedic guide and the unique intelligent algorithm for calculating screw entry point and cannulation, the robotic arm can precisely move to the planned position and provide surgeons accurate and stable placement path of K-wire. Surgeons can precisely design and place the internal implant according to surgical plan.
TiRobot find a new way to make regular surgery precise and minimally invasive, complex surgery standardized, critical operation intelligent, medical resources equally distributed, which has significant clinical advantages. The bright future of intelligent orthopedics is coming.
Full name | TINAVI Medical Technologies Co.,Ltd. |
---|---|
Abbreviations | TINAVI |
Code | 688277 |
Founded | 2010-10-22 |
Listing | 2020-07-07 |
Domicile | Beijing |
tinavi@tinavi.com | |
STAR Theme | Biomedicine |
CSRC Sector | Special equipment Manufacturing |
Has weighted voting rights structure? | No |
2020 | 2019 | 2018 | |
---|---|---|---|
Earnings Per Share | -0.14 | -0.08 | -0.00 |
R&D expenditure as a % of operating revenue | 54.53% | 33.55% | 32.74% |
Operating Revenue | 135.91 | 229.56 | 126.88 |
Net Income | -54.16 | -34.17 | -3.66 |
2020 | 2019 | 2018 | |
---|---|---|---|
Operating Revenue | 135.91 | 229.56 | 126.88 |
Operating Costs | 31.27 | 34.56 | 30.26 |
Operating Income | -64.14 | -39.47 | -8.09 |
Pretax Income | -68.40 | -42.84 | -7.99 |
Income Tax | -14.23 | -8.68 | -4.33 |
Net Income | -54.16 | -34.17 | -3.66 |
2020 | 2019 | 2018 | |
---|---|---|---|
Assets | |||
Current Assets-Total | 794.32 | 527.64 | 547.72 |
Non-current Assets-Total | 324.96 | 185.96 | 114.93 |
Total Assets | 1,119.28 | 713.60 | 662.66 |
Liabilities | |||
Current Liabilities-Total | 80.57 | 96.31 | 94.12 |
Non-current Liabilities-Total | 12.16 | 20.95 | 7.93 |
Total Liabilities | 92.73 | 117.26 | 102.05 |
Stockholder's Equity | |||
Share Capital | 1,093.62 | 640.32 | 589.72 |
Retained Profits | -97.59 | -54.98 | -38.92 |
Minority Interests | 30.52 | 11.00 | 9.81 |
Total Owners' Equity | 1,026.55 | 596.34 | 560.61 |
2020 | 2019 | 2018 | |
---|---|---|---|
Net Cash Flows-Operating | -57.58 | 20.53 | 13.15 |
Net Cash Flows-Investing | -99.76 | -147.08 | -217.63 |
Net Cash Flows-Financing | 473.11 | -2.47 | 8.76 |
Name | No. of Shares Held (mn) | % of Shares Held |
---|---|---|
Songgen Zhang | 75.66 | 18.08% |
北京智汇合创投资合伙企业(有限合伙) | 33.05 | 7.90% |
Advanced Manufacturing Industry Investment Fund(L.P.) | 25.52 | 6.10% |
Beijing - Tianjin - Hebei Industrial Cooperative Development Investment Fund(Limited Partnership) | 25.52 | 6.10% |
Beijing Runxin Dingtai Investment Center(L.P.) | 21.26 | 5.08% |
Qi Wu | 12.51 | 2.99% |
深圳同创伟业资产管理股份有限公司-北京同创共享创业投资中心(有限合伙) | 12.00 | 2.87% |
Wenjun Jiang | 11.76 | 2.81% |
萍乡市玖兆月辰投资管理合伙企业(有限合伙) | 10.92 | 2.61% |
智汇德创(天津)科技中心(有限合伙) | 9.20 | 2.20% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.